Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 646.00p 642.00p 646.00p - - - 29,431 09:05:30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 247

International Biotechnol... Share Discussion Threads

Showing 276 to 295 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
27/9/2013
11:50
Date NAV Pence Thursday 26 Sep Ex Income 334.66
davebowler
25/9/2013
12:52
Portfolio Update The Board of International Biotechnology Trust plc (the "Company") notes two unquoted portfolio events. Today the unquoted portfolio company, Ophthotech Corporation, has listed on the NASDAQ Global Select market - ticker OPHT. The Company owns 209,902 Common Stock, which are locked up and may not be traded for 180 days. Applying the Initial Public Offering price of $22 to the Company's ownership and incorporating a 2% liquidity discount to reflect the lock up terms, results in an increase in Net Asset Value of £1.2m or 2.1 pence per share above the valuation released on 24 September 2013. In addition, the unquoted portfolio company TransEnterix reverse merged with the Over The Counter Bulletin Board (OTCBB:SFES) traded SafeStitch Medical on 4 September 2013 alongside a $30m fund raising. These shares are thinly traded and so no change in valuation was made when the reverse merger took place. Our Manager has been following the trading in the shares since the merger and the 4,445,411 SafeStitch Medical shares owned by the Company are now valued at $0.40 a share, based upon the price per share of the $30m fund raising. This values the holding at £1.1m, an increase of £0.3m or 0.6 pence per share above the valuation released on 24 September 2013. Due to the thinly traded nature of the OTC market, this holding will remain in the unquoted portfolio.
davebowler
12/9/2013
08:38
Topped up 33%.
philo124
11/9/2013
15:57
Date NAV Pence Tuesday 10 Sep Ex Income 328.59 ------------ -------
davebowler
09/9/2013
11:49
Yep, this and other Bio/Tech IT's have been a good place to be.
philo124
09/9/2013
11:45
Date NAV Pence Friday 06 Sep Ex Income 323.38
davebowler
09/9/2013
11:27
hxxps://www.fidelity.co.uk/professional/perspectives/details.page?id=/templatedata/perspectives/article/data/undervaluing-innovation-in-pharma
davebowler
02/9/2013
11:57
Yep; great long term hold and balance to divi stocks.
philo124
02/9/2013
11:53
V. impressive cv
davidbh
02/9/2013
09:48
International Biotechnology Trust plc Staff Change at Investment Manager The Board of International Biotechnology Trust plc (the "Company") notes that the Company's Investment Manager, SV Life Sciences Managers LLP, has appointed Carl Harald Janson as Investment Manager, who will start with effect from today Monday, 2 September 2013. Carl Harald will be supported by Ailsa Craig to run the quoted side of the portfolio, and managing partner Kate Bingham will continue to manage the unquoted side of the portfolio. Among Carl Harald's many achievements, the outstanding performance of the Carnegie Biotechnology Fund stands out as a key highlight. During his six years and four months as its Principal Fund Manager, Carl Harald was recognised by Bloomberg as the top performing biotech fund manager worldwide. During this time period, the Carnegie Biotechnology Fund had a total return of 54% (USD) while the NASDAQ Biotechnology Index returned minus 26% (USD), a relative outperformance of approximately 80% (USD). Carl Harald is excited to be focusing on the International Biotechnology Trust portfolio, and looks forward to the challenge of again delivering excellent long term performance in an area he is passionate about. Carl Harald qualified as a medical doctor in 1981, completed his PhD in 1990 at the Karolinska Institutet, and qualified as Certified European Financial Analyst from the Stockholm School of Economics in 1999. In 1992 he joined Astra Arcus where he held various positions including Director for Preclinical Research and Development. In 1997 Carl Harald began to combine his medical and pharmaceutical industry insights with finance by working as a Senior Financial Analyst for Hagstromer & Qviberg and then Danske Securities. In 2000 he gained a role as Senior Portfolio Manager and Principal Fund Manager of the Carnegie Biotechnology Fund at Carnegie Investment Bank in Stockholm. Carl Harald responsibilities at Carnegie Investment Bank also included Fund Manager of the Carnegie Medical Fund, and the Carnegie BiotechBridge Fund. In 2008 Carl Harald was appointed Investment Manager at Karolinska Development in Stockholm, and has served as a member of the board of various Swedish biotechnology companies including Akinion Pharmaceuticals, Axelar, Aprea, Oncopeptides, and Clanotech. Since 2012 he held various chief executive roles for the Karolinska Development portfolio companies.
davebowler
06/8/2013
18:40
Pretty good progress.
philo124
06/8/2013
09:56
Date NAV Pence Friday 02 Aug Ex Income 325.85
davebowler
30/7/2013
09:38
NAV Friday 26 Jul 317.10
davebowler
24/7/2013
12:06
Date NAV Pence 23 Jul Ex Inc. 313.06 p
davebowler
17/7/2013
08:56
Prognosis: Healthy earnings for pharma, biotech www.cnbc.com/id/100890557
protean
14/7/2013
10:49
The sector is on a roll: dealbook.nytimes.com/2013/07/11/biotech-companies-surge-as-investors-flock-to-them/
protean
08/7/2013
16:00
Just topped a little for SIPP a/c.
philo124
04/7/2013
23:41
Still here.
philo124
21/6/2013
10:50
NAV Wednesday 19 Jun Ex Income 280.75
davebowler
24/5/2013
13:54
http://uk.advfn.com/news/UKREG/2013/article/57716789
davebowler
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
IBT
Internatio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190722 12:17:32